#USA #New York #Pomerantz LLP #ESSA Pharma #EPIX

Pomerantz Law Firm Takes Action Against ESSA Pharma Inc.

In a significant legal move, Pomerantz LLP has initiated a class action lawsuit against ESSA Pharma Inc., a clinical-stage pharmaceutical firm specializing in treatments for prostate cancer. The lawsuit, which has been filed with the United States District Court for the Eastern District of Wisconsin, addresses serious allegations that pertain to violations of federal securities laws by ESSA and its top executives.

Background on ESSA Pharma Inc.

Founded to innovate treatments for prostate cancer, ESSA Pharma is known for its leading candidate, masofaniten (EPI-7386), an oral small molecule androgen receptor inhibitor essential in combating prostate cancer, particularly when it becomes castration-resistant (CRPC). The pharmaceutical company has been engaged in various clinical trials to evaluate the efficacy of masofaniten alone and in combination with enzalutamide, aiming to demonstrate its potential benefits to patients.

The Class Action Lawsuit

This class action lawsuit, indexed under case number 25-cv-00124, specifically targets individuals and entities that acquired ESSA securities between December 12, 2023, and October 31, 2024. The focus of the lawsuit is to recover damages inflicted upon these investors due to misleading statements made by ESSA's executives during the class period. Pomerantz LLP claims that the defendants made substantial misrepresentations regarding ESSA's operational efficacy and the safety profile of masofaniten while failing to disclose the lack of evidence supporting the drug's effectiveness compared to existing therapies.

The suit lists several grave allegations against ESSA executives, including claims that they:
1. Misled shareholders regarding the benefits of masofaniten when combined with enzalutamide.
2. Overstated the drug's regulatory prospects and commercial viability.
3. Presented false claims about the results of their clinical trials, particularly the M-E Combination Study aiming to assess masofaniten and enzalutamide's efficacy.

The Implications of the M-E Combination Study

The M-E Combination Study, which involved a phase 1/2 trial, was central to ESSA's clinical strategy, reflecting the company's commitment to advancing prostate cancer treatment options. However, results from the interim reviews raised alarming concerns regarding the combination therapy's effectiveness. The phase 2 study, originally designed to exhibit improved outcomes, was abruptly terminated on October 31, 2024, after data indicated a lack of efficacy and clear benefits over enzalutamide monotherapy. This led to a staggering decline of about 73% in ESSA's stock price within days.

Investors Respond

Pomerantz LLP calls on any investor who purchased ESSA securities during the specified period to consider their legal options as they face potential financial losses. Investors have until March 25, 2025, to seek appointment as Lead Plaintiff in this class action. The firm encourages those wishing to participate to reach out to its offices for further discussion and legal counsel.

The Role of Pomerantz LLP

Recognized for excellence in corporate, securities, and antitrust litigation, Pomerantz LLP has a rich history of advocating for investors' rights. With over 85 years of experience, the firm remains a stalwart in the realm of class action lawsuits, aggressively pursuing reparations for fraud and corporate misconduct. ESSA Pharma's situation serves as a stark reminder to investors of the inherent risks associated with securities trading, especially in highly volatile sectors like biotechnology.

For more detailed information regarding this class action or to review the complaint, interested parties are directed to visit Pomerantz Law Firm’s website or contact their office directly. As developments continue to unfold, this lawsuit marks a significant chapter in the ongoing battle between investors and corporate transparency within the pharmaceutical industry.